Fairmont Chateau Whistler Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
Here are the related meetings in 2022:
Next Generation HIV Vaccines & Therapies (C2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Functional Cures and the Eradication of HIV (X8)
Organizer(s) Lynn Morris, Melanie M. Ott and Kevin V. Morris
March 24—28, 2019
Fairmont Chateau Whistler • Whistler, BC Canada
Discounted Abstract Deadline: Dec 5, 2018
Abstract Deadline: Dec 18, 2018
Scholarship Deadline: Dec 5, 2018
Discounted Registration Deadline: Jan 24, 2019
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Sponsored by Gilead Sciences, Inc.
Sponsored by Gilead Sciences, Inc.
Joint Meeting:
HIV Vaccines (X7)
Summary of Meeting:
Human Immunodeficiency Virus type 1 (HIV) causes a persistent infection and results in acquired immunodeficiency syndrome (AIDS). AIDS has remained a global pandemic for over 40 years as HIV integrates into the genome of infected individuals and remains latent for years. Over the last decade, much emphasis has been centered on pathogenesis and vaccine development, but an emerging paradigm is taking place whereby targeted therapeutics are being developed to both control virus expression as well as possibly target viral infected cells for eradication. This conference for the first time brings together an interdisciplinary group of basic and applied scientists working on various aspects of HIV treatment and eradication strategies in an effort to translate our current understanding of HIV biology into meaningful therapeutics and/or eradication of HIV from infected individuals. To accomplish this goal, the conference aims to: 1) Introduce the state of the art in vaccine and neutralizing antibody strategies used to combat HIV; 2) Focus on transcriptional control and modulation of viral latency; and 3) Highlight synthetic biological approaches and genetic therapies currently being developed and clinically validated to combat HIV infection. The conference seeks to bring together an interdisciplinary mix of basic and applied scientists working on functional cures and eradication of HIV in an effort to better understand not only HIV treatment strategies but also the emerging technologies and approaches that will lead to the eventual eradication of HIV from infected individuals.
View Scholarships/Awards
Human Immunodeficiency Virus type 1 (HIV) causes a persistent infection and results in acquired immunodeficiency syndrome (AIDS). AIDS has remained a global pandemic for over 40 years as HIV integrates into the genome of infected individuals and remains latent for years. Over the last decade, much emphasis has been centered on pathogenesis and vaccine development, but an emerging paradigm is taking place whereby targeted therapeutics are being developed to both control virus expression as well as possibly target viral infected cells for eradication. This conference for the first time brings together an interdisciplinary group of basic and applied scientists working on various aspects of HIV treatment and eradication strategies in an effort to translate our current understanding of HIV biology into meaningful therapeutics and/or eradication of HIV from infected individuals. To accomplish this goal, the conference aims to: 1) Introduce the state of the art in vaccine and neutralizing antibody strategies used to combat HIV; 2) Focus on transcriptional control and modulation of viral latency; and 3) Highlight synthetic biological approaches and genetic therapies currently being developed and clinically validated to combat HIV infection. The conference seeks to bring together an interdisciplinary mix of basic and applied scientists working on functional cures and eradication of HIV in an effort to better understand not only HIV treatment strategies but also the emerging technologies and approaches that will lead to the eventual eradication of HIV from infected individuals.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, March 24 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 29 in order to fully experience the meeting.
SUNDAY, MARCH 24
MONDAY, MARCH 25
TUESDAY, MARCH 26
WEDNESDAY, MARCH 27
THURSDAY, MARCH 28
FRIDAY, MARCH 29
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 24 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 29 in order to fully experience the meeting.
SUNDAY, MARCH 24
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:15
Welcome and Keynote Session (Joint)
*
Ann J. Hessell,
Oregon Health & Science University, USA
*
Sharon R. Lewin,
University of Melbourne, Australia
John R. Mascola,
NIAID, National Institutes of Health, USA
Challenges and Opportunities for Antibody-Based HIV Vaccines
Challenges and Opportunities for Antibody-Based HIV Vaccines
Robert F. Siliciano,
Johns Hopkins University School of Medicine, USA
Understanding Barriers to HIV Cure
Understanding Barriers to HIV Cure
09:15—11:15
Antibodies for Prevention, Treatment and Cure (Joint)
*
Sharon R. Lewin,
University of Melbourne, Australia
*
Ann J. Hessell,
Oregon Health & Science University, USA
David D. Ho,
Aaron Diamond AIDS Research Center (ADARC), Columbia University Medical Center, USA
Engineering Bispecific Antibodies to Prevent/Treat HIV Infection, Quantify Fc-Mediated Effector Functions, Measure Avidity Contribution to Virus Neutralization, and Infer HIV Envelope Spike Density
Engineering Bispecific Antibodies to Prevent/Treat HIV Infection, Quantify Fc-Mediated Effector Functions, Measure Avidity Contribution to Virus Neutralization, and Infer HIV Envelope Spike Density
Coffee Break
Florian Klein,
University of Cologne, Germany
Broadly Neutralizing Antibodies for HIV-1 Immunotherapy
Broadly Neutralizing Antibodies for HIV-1 Immunotherapy
Ann Marie Carias,
Northwestern University, USA
Short Talk: Distribution and Localization of I.V. injected VRC01 and VRC01-LS in the in vivo Rhesus Macaque Model
Short Talk: Distribution and Localization of I.V. injected VRC01 and VRC01-LS in the in vivo Rhesus Macaque Model
Sai Priya Anand,
McGill University, Canada
Short Talk: Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells
Short Talk: Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells
14:30—16:30
Workshop 1: Immunology of HIV Cure
*
Leor S. Weinberger,
University of California, San Francisco, USA
*
Rasmi Thomas,
U.S. Military HIV Research Program, USA
James Arthos,
NIAID, National Institutes of Health, USA
A Role for MAdCAM and Retinoic Acid in Establishing Viral Replication in Gut-Associated Lymphoid Tissues
A Role for MAdCAM and Retinoic Acid in Establishing Viral Replication in Gut-Associated Lymphoid Tissues
Evan Rossignol,
Ragon Institute of MGH, MIT, and Harvard, USA
Development of Monoclonal Antibodies from Elite Controllers to Target the HIV Reservoir
Development of Monoclonal Antibodies from Elite Controllers to Target the HIV Reservoir
Anjie Zhen,
University of California, Los Angeles, USA
Checkpoint Inhibitor Dendritic Cell Vaccine Suppresses HIV-1 Replication
Checkpoint Inhibitor Dendritic Cell Vaccine Suppresses HIV-1 Replication
David F. G. Malone,
University of Oxford, UK
CD56neg NK Cells Have Increased Functional Response to CD16 Stimulation in Chronic HIV
CD56neg NK Cells Have Increased Functional Response to CD16 Stimulation in Chronic HIV
Riddhima Banga,
Centre Hospitalier Universitaire Vaudois, Switzerland
PD-1/PD-L1 Interaction Modulates HIV-1 Transcription in Lymph Nodes of Treated Aviremic Individuals
PD-1/PD-L1 Interaction Modulates HIV-1 Transcription in Lymph Nodes of Treated Aviremic Individuals
Namita Satija,
Icahn School of Medicine at Mount Sinai, USA
A Genetically Encoded Switch to Monitor HIV Infection and Latency within Humanized Mice Reveals HIV-Susceptibility Associated with Diverse T Cell Transcriptional States
A Genetically Encoded Switch to Monitor HIV Infection and Latency within Humanized Mice Reveals HIV-Susceptibility Associated with Diverse T Cell Transcriptional States
Carly G K Ziegler,
Massachusetts Institute of Technology, USA
Paired Host-Virus Single Cell Genomics Identifies Cell Types Harboring Virus in Humans and Non-Human Primates
Paired Host-Virus Single Cell Genomics Identifies Cell Types Harboring Virus in Humans and Non-Human Primates
Alexander O. Pasternak,
University of Amsterdam, Netherlands
CD32+CD4+ T Cells Are Highly Enriched in HIV DNA
CD32+CD4+ T Cells Are Highly Enriched in HIV DNA
14:30—16:30
Workshop 1: Lessons from Non-Human Primate Studies
*
Willy Bogers,
Biomedical Primate Research Centre, Netherlands
*
Yuxing Li,
University of Maryland, USA
Bridget Fisher,
Seattle Children's Research Institute, USA
Oral Immunization with Native-Like HIV-1 Trimers Elicits Systemic Immune Responses and Cross-Clade Reactive Anti-V1V2 Antibodies
Oral Immunization with Native-Like HIV-1 Trimers Elicits Systemic Immune Responses and Cross-Clade Reactive Anti-V1V2 Antibodies
Miroslaw K. Gorny,
New York University School of Medicine, USA
Tight Control of SHIV Challenge in Macaques with Vaccine-Induced Neutralizing and Non-Neutralizing Anti-V2 Antibodies
Tight Control of SHIV Challenge in Macaques with Vaccine-Induced Neutralizing and Non-Neutralizing Anti-V2 Antibodies
Paolo Lusso,
NIAID, National Institutes of Health, USA
Induction of Cross-Clade Heterologous Tier-2 HIV-1 Neutralizing Antibodies by an mRNA-Based Vaccine in Macaques
Induction of Cross-Clade Heterologous Tier-2 HIV-1 Neutralizing Antibodies by an mRNA-Based Vaccine in Macaques
Ma Luo,
University of Manitoba, Canada
A Vaccine Targeting HIV Maturation Protects Cynomolgus Monkeys Against Vaginal SIVmac251 Acquisition
A Vaccine Targeting HIV Maturation Protects Cynomolgus Monkeys Against Vaginal SIVmac251 Acquisition
Mauricio A. Martins,
University of Miami, USA
Anti-CTLA-4 Therapy Enhances Vaccine Immunogenicity but not Efficacy Against Simian Immunodeficiency Virus Challenge in Rhesus Macaques
Anti-CTLA-4 Therapy Enhances Vaccine Immunogenicity but not Efficacy Against Simian Immunodeficiency Virus Challenge in Rhesus Macaques
Kimberly M. Cirelli,
La Jolla Institute for Immunology, USA
Slow Delivery Immunization Enhances Germinal Center and Neutralizing Antibody Responses via Modulation of Immunodominance
Slow Delivery Immunization Enhances Germinal Center and Neutralizing Antibody Responses via Modulation of Immunodominance
Mario Roederer,
NIAID, National Institutes of Health, USA
SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding
SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding
17:00—19:00
Development of the Innate Cell and Antibody Responses to HIV
*
Rebecca M. Lynch,
George Washington University, USA
*
Brian Moldt,
Gilead Sciences, USA
Galit Alter,
MIT and Harvard University, USA
Defining Conserved Correlates of Humoral Immune Protection Against SIV/SHIV
Defining Conserved Correlates of Humoral Immune Protection Against SIV/SHIV
Michel C. Nussenzweig,
HHMI/Rockefeller University, USA
Targeting B Lymphocytes to Control HIV-1
Targeting B Lymphocytes to Control HIV-1
Mario Roederer,
NIAID, National Institutes of Health, USA
Short Talk: SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding
Short Talk: SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding
Jérémy Dufloo,
Institut Pasteur, France
Short Talk: Complement Activation at the Surface of HIV-1-Infected Cells
Short Talk: Complement Activation at the Surface of HIV-1-Infected Cells
Mariya B. Shapiro,
Oregon Health & Science University, USA
Short Talk: Defining the Window of Opportunity for SHIV Clearance with bNAbs in Infant Macaques
Short Talk: Defining the Window of Opportunity for SHIV Clearance with bNAbs in Infant Macaques
Lynn Morris,
National Institute for Communicable Diseases, South Africa
Genetic and Structural Features of HIV-1 V2-Specific Antibodies that Mediate ADCC and Block α4β7 Interactions
Genetic and Structural Features of HIV-1 V2-Specific Antibodies that Mediate ADCC and Block α4β7 Interactions
17:00—19:00
Clinical Trials for Prevention: Vaccines and Antibodies
*
Susan W. Barnett,
Bill & Melinda Gates Foundation, USA
*
Punnee Pitisuttithum,
Mahidol University, Thailand
Shelly Krebs,
Walter Reed Army Institute of Research, USA
Short Talk: B Cell Priming from RV144 Vaccination Impacts Post-Infection Antibody Responses
Short Talk: B Cell Priming from RV144 Vaccination Impacts Post-Infection Antibody Responses
Lawrence Corey,
Fred Hutchinson Cancer Research Center, USA
Validating Neutralization as a Mechanistic Surrogate of Protection in Passive Antibody Studies
Validating Neutralization as a Mechanistic Surrogate of Protection in Passive Antibody Studies
Beatrice Ondondo,
Cardiff Metropolitan University, UK
T-Cell Vaccine Trials for HIV
T-Cell Vaccine Trials for HIV
R. Keith Reeves,
Harvard Medical School, USA
Short Talk: Human Memory NK Cells Are Potently Induced by HIV and HIV Vaccines
Short Talk: Human Memory NK Cells Are Potently Induced by HIV and HIV Vaccines
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Mechanisms of Viral Expression and Control of Host Cell Function
*
Ya-Chi Ho,
Yale School of Medicine, USA
*
Joseph (Mike) McCune,
Bill & Melinda Gates Foundation, USA
Saba Valadkhan,
Case Western Reserve University, USA
An HIV-Induced Mechanism for T Cell Quiescence and Proviral Latency
An HIV-Induced Mechanism for T Cell Quiescence and Proviral Latency
Eric M. Verdin,
Buck Institute for Research on Aging, USA
CRISPR-Based Characterizing of Latency-Associated Pathways
CRISPR-Based Characterizing of Latency-Associated Pathways
Coffee Break
Jonathan Karn,
Case Western Reserve University, USA
Signaling Pathways Controlling HIV Reactivation from Latency
Signaling Pathways Controlling HIV Reactivation from Latency
Ivan D'Orso,
University of Texas Southwestern Medical Center, USA
Transcriptional Regulatory Mechanisms Shaping HIV Proviral Fate
Transcriptional Regulatory Mechanisms Shaping HIV Proviral Fate
Joe D. Hiatt,
University of California, San Francisco, USA
Short Talk: A Functional Map of HIV-Host Interactions in Primary Human CD4+ T cells
Short Talk: A Functional Map of HIV-Host Interactions in Primary Human CD4+ T cells
Peter D. Sun,
NIAID, National Institutes of Health, USA
Short Talk: Target HIV Viral Release Pathway as A New Antiviral Strategy
Short Talk: Target HIV Viral Release Pathway as A New Antiviral Strategy
Richard E. Sutton,
Yale University School of Medicine, USA
Short Talk: Whole Exome Sequencing Identifies SNVs and Indels Associated with HIV+ Elite and Viremic Control
Short Talk: Whole Exome Sequencing Identifies SNVs and Indels Associated with HIV+ Elite and Viremic Control
08:00—11:15
New Technologies for Studying and Inducing B Cells
*
Ivelin Georgiev,
Vanderbilt Vaccine Center, USA
*
Andrew B. Ward,
The Scripps Research Institute, USA
Gunilla B. Karlsson Hedestam,
Karolinska Institutet, Sweden
Antibody Germline Genes and Impact on Vaccine Responses
Antibody Germline Genes and Impact on Vaccine Responses
Steven E. Bosinger,
Emory University, USA
In vivo Lineage Tracing of Antigen-Specific B Cells after Vaccination
In vivo Lineage Tracing of Antigen-Specific B Cells after Vaccination
Ian Setliff,
Vanderbilt Vaccine Center, USA
Short Talk: High-Throughput Mapping of B-Cell Receptor Sequence to Antigen Specificity
Short Talk: High-Throughput Mapping of B-Cell Receptor Sequence to Antigen Specificity
Coffee Break
James E. Voss,
The Scripps Research Institute, USA
Short Talk: Reprogramming the Antigen Specificity of B Cells Using Genome-Editing Technologies
Short Talk: Reprogramming the Antigen Specificity of B Cells Using Genome-Editing Technologies
Adrian B. McDermott,
National Institutes of Health, USA
Characterization of Antigen-Specific Memory B Cells Following Vaccination
Characterization of Antigen-Specific Memory B Cells Following Vaccination
Colin Havenar-Daughton,
Vir Biotechnology, USA
The Antigen-Specific Human Naive B Cell Repertoire: A Starting Point for Vaccine Responses
The Antigen-Specific Human Naive B Cell Repertoire: A Starting Point for Vaccine Responses
Kristin L. Boswell,
NIAID, National Institutes of Health, USA
Short Talk: Bcl-6/Bcl-xL B Cell Immortalization for Antibody Discovery in Vaccination and Chronic Infection
Short Talk: Bcl-6/Bcl-xL B Cell Immortalization for Antibody Discovery in Vaccination and Chronic Infection
11:30—13:00
Hands-On Computer Workshop on Los Alamos
HIV Sequences Database
Bring your own laptop if you have one
Click here for more information
Click here for more information
17:00—19:00
Mechanism and Modulation of Latency
*
George B. Kyei,
University of Ghana, Ghana
*
Sharon R. Lewin,
University of Melbourne, Australia
Monsef Benkirane,
Institut de Genetique Humaine, France
HIV-Host Interactions at the Genomic Level
HIV-Host Interactions at the Genomic Level
Leor S. Weinberger,
University of California, San Francisco, USA
Discovery and Characterization of a Virus-Intrinsic HIV Latency Circuit
Discovery and Characterization of a Virus-Intrinsic HIV Latency Circuit
Luis M. Agosto,
Boston Medical Center, USA
Short Talk: Identification of Novel Pathways that Regulate HIV Transcription using an Unbiased Functional Screen
Short Talk: Identification of Novel Pathways that Regulate HIV Transcription using an Unbiased Functional Screen
Leah Plasek,
Case Western Reserve University, USA
Short Talk: Investigation of Potential Roles for lncRNAs in Establishment and Maintenance of HIV Latency
Short Talk: Investigation of Potential Roles for lncRNAs in Establishment and Maintenance of HIV Latency
17:00—19:00
Antibody-Virus Coevolution: Vaccines and Lessons from Infection
*
Daniela Fera,
Swarthmore College, USA
Nicole A. Doria-Rose,
NIAID, National Institutes of Health, USA
Broadly Neutralizing Antibodies: Lessons from Natural Infection
Broadly Neutralizing Antibodies: Lessons from Natural Infection
Kevin O. Saunders,
Duke University, USA
Short Talk: CH505 Transmitted/Founder Envelope Elicits Tier 2 Neutralizing Antibodies Against the CD4 Binding and V1V2-Glycan Sites during Human Infection and Macaque Vaccination
Short Talk: CH505 Transmitted/Founder Envelope Elicits Tier 2 Neutralizing Antibodies Against the CD4 Binding and V1V2-Glycan Sites during Human Infection and Macaque Vaccination
Mattia Bonsignori,
Duke University, USA
Inference of the VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
Inference of the VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
Elise Landais,
International AIDS Vaccine Initiative, USA
Fast and Focused Maturation of a VRC01-Class Broadly Neutralizing Antibody Lineage
Fast and Focused Maturation of a VRC01-Class Broadly Neutralizing Antibody Lineage
Marit van Gils,
Amsterdam UMC, Netherlands
Short Talk: Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and BG505 SHIV Infection in Non-Human Primates
Short Talk: Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and BG505 SHIV Infection in Non-Human Primates
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Therapeutic Vaccines and Cure Strategies (Joint)
*
Douglas F. Nixon,
Weill Cornell Medicine, USA
*
Tomas Hanke,
University of Oxford, UK
Jintanat Ananworanich,
US Military HIV Research Program, USA
AD26 & MVA Vaccines in Acutely Treated HIV: Safety, Immunogenicity and Viral Rebound
AD26 & MVA Vaccines in Acutely Treated HIV: Safety, Immunogenicity and Viral Rebound
Beatriz Mothe,
IrsiCaixa AIDS Research Institute-HIVACAT, Spain
Therapeutic Vaccines after Early ART: Impact on Reservoir
Therapeutic Vaccines after Early ART: Impact on Reservoir
Coffee Break
Warner Craig Greene,
Gladstone Institute of Virology and Immunology, USA
Attacking the Latent Reservoir with Convertible CAR-T Cells Programmed with HIV bNAbs
Attacking the Latent Reservoir with Convertible CAR-T Cells Programmed with HIV bNAbs
Eric Arts,
Western University, Canada
Combining a TLR7 Agonist with a Heterologous Virus-Like Particle for Potent and Specific Latency Reversal in Patient Samples during Stable cART
Combining a TLR7 Agonist with a Heterologous Virus-Like Particle for Potent and Specific Latency Reversal in Patient Samples during Stable cART
11:30—13:00
Hands-On Computer Workshop on Los Alamos
HIV Immunology Database
Bring your own laptop if you have one
Click here for more information
Click here for more information
14:30—16:30
Workshop 2: Understanding Antibody and Envelope Structures
*
Linqi Zhang,
Tsinghua University, China
*
Alejandro Balazs,
Massachusetts General Hospital, USA
Jacqueline Marlene Brady,
Harvard Medical School, USA
Isotype-Dependent Protection Against Mucosal HIV Transmission in Humanized Mouse Models
Isotype-Dependent Protection Against Mucosal HIV Transmission in Humanized Mouse Models
Samantha Marie Townsley,
Walter Reed Army Institute of Research, USA
Autoreactivity Mediated by Total IgG Is not Associated with the Development of Neutralization Breadth
Autoreactivity Mediated by Total IgG Is not Associated with the Development of Neutralization Breadth
Michael B. Zwick,
The Scripps Research Institute, USA
An MPER Antibody that Neutralizes HIV Using Recognition Properties and Germline Genes Shared Among Donors
An MPER Antibody that Neutralizes HIV Using Recognition Properties and Germline Genes Shared Among Donors
Rory Henderson,
Duke University, USA
Antibody Fab Elbow Mutations Modulate Interdomain Flexibility and Dynamics of HIV-1 Broadly Neutralizing Antibodies
Antibody Fab Elbow Mutations Modulate Interdomain Flexibility and Dynamics of HIV-1 Broadly Neutralizing Antibodies
Ronnie M. Russell,
University of Pennsylvania, USA
Antigenic Conservation of the V2 Apex Among Primate Lentiviruses
Antigenic Conservation of the V2 Apex Among Primate Lentiviruses
Marie Pancera,
Fred Hutchinson Cancer Research Center, USA
Structural Basis for Potent Tier 2 Autologous Neutralization Elicited by Vaccination
Structural Basis for Potent Tier 2 Autologous Neutralization Elicited by Vaccination
Andres Finzi,
CRCHUM, Université de Montréal, Canada
An Asymmetric Opening of HIV-1 Env Is Required for Anti-Cluster A Antibody Binding
An Asymmetric Opening of HIV-1 Env Is Required for Anti-Cluster A Antibody Binding
Kimmo Rantalainen,
The Scripps Research Institute, USA
Electron Microscopic Characterization of HIV Envelope in Detergent Micelles, Lipid Bicelles and Nanodiscs
Electron Microscopic Characterization of HIV Envelope in Detergent Micelles, Lipid Bicelles and Nanodiscs
17:00—19:00
Experimental Molecular Approaches to Targeting Viral Reservoirs
*
Ramesh K. Akkina,
Colorado State University, USA
*
Paula M. Cannon,
University of Southern California, Keck School of Medicine, USA
Romas Geleziunas,
Gilead Sciences, Inc., USA
Attacking Latent Reservoirs
Attacking Latent Reservoirs
Priti Kumar,
Yale School of Medicine, USA
Direct in vivo Gene Engineering of Human T Cells for HIV Therapy
Direct in vivo Gene Engineering of Human T Cells for HIV Therapy
Chantelle L. Ahlenstiel,
Kirby Institute, University of New South Wales, Australia
Short Talk: RNA-Directed Epigenetic Silencing Protects Humanized Mice during HIV Challenge
Short Talk: RNA-Directed Epigenetic Silencing Protects Humanized Mice during HIV Challenge
Fabio Romerio,
University of Maryland School of Medicine, USA
Short Talk: The HIV-1 Antisense Transcript Ast Induces Viral Latency via Several Silencing Pathways
Short Talk: The HIV-1 Antisense Transcript Ast Induces Viral Latency via Several Silencing Pathways
17:00—19:00
T Cells in HIV Vaccination and Acute Infection
*
Barbara L. Shacklett,
University of California, Davis, USA
*
Diane L. Bolton,
US Military HIV Research Program, WRAIR, USA
Christian Brander,
Institut de Recerca de la Sida, IrsiCaixa, Spain
Vaccine-Elicited T Cells in Clinical Trials
Vaccine-Elicited T Cells in Clinical Trials
Stephen A. Migueles,
NIAID, National Institutes of Health, USA
Short Talk: Ad5/HIV Vaccines Induce CD8+ T Cells with Insufficient Avidity to Kill HIV-Infected CD4+ T Cells
Short Talk: Ad5/HIV Vaccines Induce CD8+ T Cells with Insufficient Avidity to Kill HIV-Infected CD4+ T Cells
David B. Masopust,
University of Minnesota, USA
Tissue-Resident T Cells
Tissue-Resident T Cells
Jonah B. Sacha,
Oregon Health & Science University, USA
Unconventional T Cells: Potential for Induction by Vaccination
Unconventional T Cells: Potential for Induction by Vaccination
Leticia Kuri-Cervantes,
University of Pennsylvania, USA
Short Talk: Longitudinal Dynamics of Follicular CD4+ T Cells in Acute SIV Infection
Short Talk: Longitudinal Dynamics of Follicular CD4+ T Cells in Acute SIV Infection
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Targeting and Eradication of HIV
*
Zabrina L. Brumme,
Simon Fraser University, Canada
*
Eric M. Verdin,
Buck Institute for Research on Aging, USA
David M. Margolis,
University of North Carolina at Chapel Hill, USA
Progress Towards Targeting and Eradication of HIV in Models and Man
Progress Towards Targeting and Eradication of HIV in Models and Man
Sharon R. Lewin,
University of Melbourne, Australia
Understanding Natural Variation in HIV Transcription on Antiretroviral Therapy: New Approaches to Reverse HIV Latency
Understanding Natural Variation in HIV Transcription on Antiretroviral Therapy: New Approaches to Reverse HIV Latency
Coffee Break
Deborah Persaud,
Johns Hopkins University School of Medicine, USA
Latency and HIV in Pediatric Populations
Latency and HIV in Pediatric Populations
Lucy Dorrell,
University of Oxford, UK
Novel Engineered Immune-Mobilizing T Cell Receptors-Based Drugs (‘ImmTAVs’) to Clear HIV Infection
Novel Engineered Immune-Mobilizing T Cell Receptors-Based Drugs (‘ImmTAVs’) to Clear HIV Infection
Bojana Lucic,
Universität Heidelberg, Germany
Short Talk: 3D Genome Conformation is the Major Determinant of HIV-1 Integrational Hot-Spots
Short Talk: 3D Genome Conformation is the Major Determinant of HIV-1 Integrational Hot-Spots
Alberto Bosque,
George Washington University, USA
Short Talk: In vitro, ex vivo and in vivo Analysis of Benzotriazine Derivatives as Latency-Reversing Agents
Short Talk: In vitro, ex vivo and in vivo Analysis of Benzotriazine Derivatives as Latency-Reversing Agents
Marion Pardons,
Université de Montréal, CRCHUM, Canada
Short Talk: Latency Reversing Agents Induce Differential Responses in Distinct Memory CD4+ T Cell Subsets
Short Talk: Latency Reversing Agents Induce Differential Responses in Distinct Memory CD4+ T Cell Subsets
08:00—11:15
Env Immunogen Design and Evaluation
*
Ralf Wagner,
Universität Regensburg, Germany
*
James Mark Binley,
San Diego Biomedical Research Institute, USA
Richard T. Wyatt,
IAVI Neutralizing Antibody Center, The Scripps Research Institute, USA
NFL Trimers: Down the Rabbit Hole and Other Unlikely Events
NFL Trimers: Down the Rabbit Hole and Other Unlikely Events
David Peterhoff,
University Regensburg, Germany
Short Talk: Stabilized HIV-1 Clade C Envelope Trimers with Increased Stability and Preferential Antigenic Properties in vitro and in vivo
Short Talk: Stabilized HIV-1 Clade C Envelope Trimers with Increased Stability and Preferential Antigenic Properties in vitro and in vivo
Tongqing Zhou,
NIAID, National Institutes of Health, USA
Native Glycan Shield Is Important for Inducing Immune Responses that Neutralize Diverse Tier-2 Viruses in Sequential HIV-1 Env Trimer Immunization
Native Glycan Shield Is Important for Inducing Immune Responses that Neutralize Diverse Tier-2 Viruses in Sequential HIV-1 Env Trimer Immunization
Coffee Break
Andrew J. Borst,
University of Washington, USA
Short Talk: Germline VRC01 Antibody Recognition of a Modified Clade C HIV-1 Envelope Trimer and a Glycosylated HIV-1 gp120 Core
Short Talk: Germline VRC01 Antibody Recognition of a Modified Clade C HIV-1 Envelope Trimer and a Glycosylated HIV-1 gp120 Core
Karin Loré,
Karolinska Institutet, Sweden
In vivo Fate of Env and Early Responses upon Immunization
In vivo Fate of Env and Early Responses upon Immunization
Derek T. O'Hagan,
GlaxoSmithKline Vaccines, USA
Designing and Building the Next Generation of Vaccine Adjuvants
Designing and Building the Next Generation of Vaccine Adjuvants
Aleksandar Antanasijevic,
The Scripps Research Institute, USA
Short Talk: Development of Self-Assembling Nanoparticle Systems for Presentation of HIV Env Trimers
Short Talk: Development of Self-Assembling Nanoparticle Systems for Presentation of HIV Env Trimers
14:30—16:30
Workshop 2: LRA and New Antiviral Strategies
*
Susana T. Valente,
Scripps Florida, USA
*
Tristan Alexander Scott,
City of Hope, USA
Ya-Chi Ho,
Yale School of Medicine, USA
Filgotinib, a Janus Kinase Inhibitor, Suppresses HIV-1 Expression and T Cell Activation
Filgotinib, a Janus Kinase Inhibitor, Suppresses HIV-1 Expression and T Cell Activation
Haitao Hu,
University of Texas Medical Branch, USA
A Novel Small Molecule Modulating BRD4 to Epigenetically Suppress HIV
A Novel Small Molecule Modulating BRD4 to Epigenetically Suppress HIV
Seohyun Ahn,
ST Pharm. Co., Ltd., South Korea
A Highly Potent and Safe Allosteric HIV-1 Integrase Inhibitor: Virological, Molecular and Preclinical Characterization of STP0404
A Highly Potent and Safe Allosteric HIV-1 Integrase Inhibitor: Virological, Molecular and Preclinical Characterization of STP0404
Konstantinos Georgiou,
University of California, San Francisco, USA
Single-Cell Sequencing Reveals Transcriptome and Surfaceome Signatures of HIV Latently-Infected Cells
Single-Cell Sequencing Reveals Transcriptome and Surfaceome Signatures of HIV Latently-Infected Cells
Vera Klemm,
Kirby Institute, Australia
Nanoparticle Delivery of Epigenetic Silencing siRNA to the Nucleus of HIV-1-Infected Cells
Nanoparticle Delivery of Epigenetic Silencing siRNA to the Nucleus of HIV-1-Infected Cells
George B. Kyei,
University of Ghana, Ghana
Splicing Factor 3B Subunit 1 Interacts HIV Tat and Can Be Targeted to Prevent Viral Transcription and Reactivation from Latency
Splicing Factor 3B Subunit 1 Interacts HIV Tat and Can Be Targeted to Prevent Viral Transcription and Reactivation from Latency
Ulf Dittmer,
University of Duisburg-Essen, Germany
HIV Cure Strategies with Interferon Alpha Subtype 14 in HIV-1 Infected Humanized Mice
HIV Cure Strategies with Interferon Alpha Subtype 14 in HIV-1 Infected Humanized Mice
Miriam Rosas-Umbert,
AIDS Research Institute Irsicaixa – HIVACAT, Spain
In vivo Effects of Romidepsin in the Bcn02 Kick&Kill Trial for HIV Remission
In vivo Effects of Romidepsin in the Bcn02 Kick&Kill Trial for HIV Remission
17:00—18:45
Protect and Kill Strategies to a Functional Cure
*
Warner Craig Greene,
Gladstone Institute of Virology and Immunology, USA
*
Betty Poon,
NIAID, National Institutes of Health, USA
Paula M. Cannon,
University of Southern California, Keck School of Medicine, USA
Genome Engineering Strategies to Generate HIV-Resistant Cells
Genome Engineering Strategies to Generate HIV-Resistant Cells
Scott G. Kitchen,
University of California, Los Angeles AIDS Institute, USA
Engineering Long-Term HIV-Specific Immunity through Chimeric Antigen Receptors and Stem Cells
Engineering Long-Term HIV-Specific Immunity through Chimeric Antigen Receptors and Stem Cells
Kevin V. Morris,
Center for Gene Therapy, City of Hope, USA
Flare, Excise, Kill: Means to a Functional Cure for HIV
Flare, Excise, Kill: Means to a Functional Cure for HIV
Chris Peterson,
Fred Hutchinson Cancer Research Center, USA
Short Talk: Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates
Short Talk: Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates
17:00—18:45
From the Lab to the Clinic: A Reality Check for Investigators
*
Devin Sok,
International AIDS Vaccine Initiative, USA
*
Silvija I. Staprans,
Bill & Melinda Gates Foundation, USA
Mark Connors,
NIAID, National Institutes of Health, USA
Impact of Immunogen Design and Replication on Pre-Clinical and Clinical Immunogenicity
Impact of Immunogen Design and Replication on Pre-Clinical and Clinical Immunogenicity
Peter D. Kwong,
NIAID, National Institutes of Health, USA
Short Talk: Steps Toward a Fusion Peptide-Based Vaccine
Short Talk: Steps Toward a Fusion Peptide-Based Vaccine
Hanneke Schuitemaker,
Janssen Vaccines & Prevention B.V., Netherlands
Advancing an HIV Vaccine Candidate through the Development Pipeline: A View from Industry
Advancing an HIV Vaccine Candidate through the Development Pipeline: A View from Industry
Antu K. Dey,
International AIDS Vaccine Initiative, USA
Translation of Multiple Products from Discovery to the Clinic: The View from a Product Development Center at a Non-Profit Organization
Translation of Multiple Products from Discovery to the Clinic: The View from a Product Development Center at a Non-Profit Organization
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
